These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33037136)

  • 1. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
    Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
    Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
    Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
    Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
    Gerson-Gurwitz A; Young NP; Goel VK; Eam B; Stumpf CR; Chen J; Fish S; Barrera M; Sung E; Staunton J; Chiang GG; Webster KR; Thompson PA
    Front Oncol; 2021; 11():766298. PubMed ID: 34900714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.
    Tsai BP; Jimenez J; Lim S; Fitzgerald KD; Zhang M; Chuah CT; Axelrod H; Wilson L; Ong ST; Semler BL; Waterman ML
    Open Biol; 2014 Nov; 4(11):140180. PubMed ID: 25392452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eIF4B stimulates eIF4A ATPase and unwinding activities by direct interaction through its 7-repeats region.
    Andreou AZ; Harms U; Klostermeier D
    RNA Biol; 2017 Jan; 14(1):113-123. PubMed ID: 27858515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
    Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
    Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
    Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
    Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eIF4B stimulates translation of long mRNAs with structured 5' UTRs and low closed-loop potential but weak dependence on eIF4G.
    Sen ND; Zhou F; Harris MS; Ingolia NT; Hinnebusch AG
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10464-72. PubMed ID: 27601676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
    Ernst JT; Thompson PA; Nilewski C; Sprengeler PA; Sperry S; Packard G; Michels T; Xiang A; Tran C; Wegerski CJ; Eam B; Young NP; Fish S; Chen J; Howard H; Staunton J; Molter J; Clarine J; Nevarez A; Chiang GG; Appleman JR; Webster KR; Reich SH
    J Med Chem; 2020 Jun; 63(11):5879-5955. PubMed ID: 32470302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest.
    Han L; Wu Y; Liu F; Zhang H
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
    Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
    Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of small molecules targeting eIF4A.
    Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
    RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.
    Modelska A; Turro E; Russell R; Beaton J; Sbarrato T; Spriggs K; Miller J; Gräf S; Provenzano E; Blows F; Pharoah P; Caldas C; Le Quesne J
    Cell Death Dis; 2015 Jan; 6(1):e1603. PubMed ID: 25611378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death 4 mechanism of action: The model to be updated?
    Vikhreva PN; Kalinichenko SV; Korobko IV
    Cell Cycle; 2017 Oct; 16(19):1761-1764. PubMed ID: 28853972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
    Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
    Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
    Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
    Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.
    Yang HS; Cho MH; Zakowicz H; Hegamyer G; Sonenberg N; Colburn NH
    Mol Cell Biol; 2004 May; 24(9):3894-906. PubMed ID: 15082783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.